The purpose of this study was to determine whether asthma control and reduced bronchial hyperresponsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS twice-daily or FP twice-daily in adult and adolescent subjects with persistent asthma
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
464
Average inhaled corticosteroid treatment dose over the treatment period
Time frame: Every 8 weeks for the 40 week treatment period
Pulmonary function measures
Time frame: Every 8 weeks for the 40 week treatment period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Twice daily dosing
Twice daily dosing
Twice daily dosing
Twice daily dosing
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Tucson, Arizona, United States
GSK Investigational Site
Carmichael, California, United States
GSK Investigational Site
Palmdale, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Jose, California, United States
GSK Investigational Site
San Jose, California, United States
...and 48 more locations